Back to Explorer

Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act

DraftCenter for Drug Evaluation and Research Center for Biologics Evaluation and Research07/11/2014

Description

This guidance document is intended to assist persons reporting drug sample distribution information2 to FDA under section 6004 of the Patient Protection and Affordable Care Act (ACA).

Scope & Applicability

Product Classes

2
Drug sample

Unit of prescription drug not intended to be sold

applicable drugs

Drugs for which sample information must be reported under ACA

Stakeholders

6
ADR

authorized distributors of record required to report drug sample data

physician

medical professional requesting HCT/P for urgent need; requesting HCT/P based on urgent medical need

Authorized distributor of record

Distributors with an ongoing relationship with a manufacturer

practitioner

Licensed professional making the drug sample request; Licensed individual who requests drug samples

authorized distributors of record

ADRs required to report drug sample information

manufacturer

Entity required to conduct postmarket surveillance; entity responsible for submitting postmarket surveillance plans; Entity holding the approved PMA, HDE, or cleared 510(k); The entity responsible for conducting postmarket surveillance and submitting reports.; Entity that can use the checklist as a reference for submissions.

Regulatory Context

Attributes

1
professional designation

Information required to be aggregated in the report; Required data element for practitioner identification

Related CFR Sections (4)

See Also (5)

Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act | Guideline Explorer | BioRegHub